AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1 (currently amended) A method of treating inflammation comprising administering a therapeutically effective amount of a pharmaceutical/cosmetic composition of matter, comprising an anti-inflammatory effective amount of at least one peptide comprising the lysine-proline-valine tripeptide sequence, the proline and valine ~~moiety~~ moieties of which ~~exists~~ exist in ~~its~~ dextrorotatory optical isomer form ~~(DPro)~~ (D-Pro-D-Val), wherein said peptide comprises anti-inflammatory activity, in a physiologically/pharmaceutically acceptable medium therefor, and ~~where~~ wherein the lysine ~~and valine residues contained~~ residue in said lysine-proline-valine tripeptide sequence ~~exist~~ exists either in ~~their~~ levorotatory ~~of~~ or dextrorotary ~~forms~~ form.

Claim 2 (previously presented) The method as defined in Claim 1, said tripeptide sequence comprising the last three amino acids situated at the C-terminal end of said at least one peptide.

Claim 3 (canceled)

Claim 4 (currently amended) The method as defined in Claim 1, said at least one peptide comprising the lysine-proline-valine tripeptide, the lysine, proline and valine moieties of which exist in ~~their~~ dextrorotatory optical isomer ~~forms~~ form (D-Lys-D-Pro-D-Val).

Claim 5 (previously presented) The method as defined in Claim 1, said at least one peptide including at least one protective group situated at the C-terminal and/or N-terminal end of said peptide.

Claim 6 (previously presented) The method as defined in Claim 5, wherein said at least one protective group comprises an acyl, acetyl and/or amido group.

Claim 7 (previously presented) The method as defined in Claim 1, wherein said composition comprises from 10^{-12}M to 10^{-3}M of said tripeptide sequence.

Claim 8 (previously presented) The method as defined in Claim 7, wherein said composition comprises from 10^{-9}M to 10^{-4}M of said tripeptide sequence.

Claim 9 (previously presented) The method as defined in Claim 1, wherein said composition comprises from 10^{-12}M to 1M of said tripeptide sequence.

Claim 10 (previously presented) The method as defined in Claim 9, wherein said composition comprises from 10^{-6}M to 10^{-1}M of said tripeptide sequence.

Claim 11 (previously presented) The method as defined in Claim 1, wherein said composition comprises a lotion, gel, milk, serum, cream, sunscreen, emulsion, shampoo, dentifrice, ointment, aerosol or spray.

Claims 12-15 (canceled)

Claim 16 (previously presented) The method according to Claim 1, wherein the pharmaceutical/cosmetic composition is topically applied.

Claim 17 (previously presented) The method according to Claim 1, wherein the pharmaceutical/cosmetic composition is topically applied to the skin, scalp and/or mucous membrane of a mammalian organism.

Claim 18 (previously presented) The method according to Claim 1, wherein the pharmaceutical/cosmetic composition which is administered further comprises an effective anti-inflammatory amount of at least one glucocorticoid, vitamin D or derivative thereof, and/or non-steroidal anti-inflammatory agent.

Claim 19 (currently amended) The method according to Claim 1, wherein said lysine-proline-valine tripeptide sequence contained in said pharmaceutical/cosmetic composition is acidyl-(D) Lys-(D) Pro-(D) Val-NH_2 ~~or acidyl-(L) Lys-(D) Pro-(L) Val-NH_2~~.

Claim 20 (new) A method of treating inflammation comprising administering a therapeutically effective amount of a pharmaceutical/cosmetic composition of matter, comprising an anti-inflammatory effective amount of at least one peptide comprising the lysine-proline-valine tripeptide sequence, the proline and lysine moieties of which exist in dextrorotatory optical isomer form (D-Lys-D-Pro), wherein said peptide comprises anti-inflammatory activity, in a physiologically/pharmaceutically acceptable medium therefor, and wherein the valine in said lysine-proline-valine tripeptide sequence exists either in levorotatory or dextrorotary form.